CJC-1295 + DAC (Drug Affinity Complex)

Extended-Stability Growth Hormone Secretagogue

Executive Summary

CJC-1295 with DAC represents a significant engineering advancement in the field of Growth Hormone-Releasing Hormone (GHRH) analogues. By modifying the first 29 amino acids of GHRH (Modified GRF 1-29) through tetrasubstitution and the addition of the Drug Affinity Complex (DAC), this peptide achieves a pharmacokinetic profile previously unattainable with native GHRH.

The DAC Innovation

The defining characteristic of this compound is its ability to utilize bioconjugation. The DAC—comprised of a lysine residue linked to a maleimidopropionic acid group—enables the peptide to form a covalent bond with circulating serum albumin.

• Enzymatic Protection: This albumin-binding shields the peptide from rapid proteolysis by Dipeptidyl peptidase-IV (DPP-IV).

• Pharmacokinetic Shift: Extends the biological half-life from a few minutes to an estimated 6–8 days.

• Research Focus: Studied for its ability to maintain elevated levels of IGF-1 and promote a steady-state release of endogenous growth hormone, avoiding the “peaks and troughs” associated with short-acting secretagogues.

Chemical & Physical Properties

Handling & Storage Guidelines

To ensure maximum stability and biological activity, strict temperature control is required:

• Long-Term Storage (Lyophilized): Store at -20°C.

• Post-Reconstitution: Once dissolved in bacteriostatic or sterile water, store at 2–8°C.

• Stability Note: Avoid repeated freeze-thaw cycles and minimize exposure to direct light.

Institutional Research Disclaimer

WARNING: This product is strictly synthesized for Laboratory Research Use Only. It is not approved for human consumption, therapeutic intervention, veterinary use, or clinical diagnostics. All research should be conducted in an appropriately equipped facility by qualified personnel.